US Patent

US9339489 — Rapid disperse dosage form containing levetiracetam

Method of Use · Assigned to Aprecia Pharmaceuticals Co · Expires 2034-03-14 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

A high dose of levetiracetam (Keppra) in a porous matrix is disclosed in a rapidly dispersing dosage form that dissolves in water within 10 seconds.

USPTO Abstract

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

Drugs covered by this patent

Keppra (levetiracetam) · Generic (originally UCB Pharma)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1850`	—	Keppra
`U-1850`	—	Keppra
`U-1850`	—	Keppra
`U-1850`	—	Keppra

Patent Metadata

Patent number: US9339489
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Aprecia Pharmaceuticals Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.